Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: a double-blind, randomized dose-response study (vol 91, pg 1191, 2001)
Jr. Berenson et al., Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: a double-blind, randomized dose-response study (vol 91, pg 1191, 2001), CANCER, 91(10), 2001, pp. 1956-1956